Replies to post #205120 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Yep, Bryostatin doesn't target anything in the disease process.

It's all based on short term trial analysis.

Reference my previous analogy.. jump start a dead battery and you will get home but you won't get to work on time the next morning.

This is exactly what I would expect from long term testing of Bryosatin and solid justification for those seeking to profit from the IPO an manipulation of the stock sincerely avoiding these issues.

[seventhwave]

runcoach, I'm sure you know bryostatin has a very narrow therapeutic window (if any) which NTRP is trying to finesse with. Their trial result in Apr 2017 couldn't demonstrate a positive dose response effect. In fact, NTRP has failed to release trial data for the entire higher dose cohort (or half the original 147 patient trial.) Why do you put faith in a company that openly manipulates.

NTRP has targeted a placebo-adjusted improvement in the SIB of 2.6 points at 3 months for bryostatin, which is not clinically meaningful. By comparison, the Pfizer's Alzheimer's drug Aricept showed a placebo-adjusted change in the SIB of 5.9 points after six months. So NTRP is chasing an endpoint which will not be rewarded by investors.

Diarrhea is a very lousy side effect to have in the geriatric population. A2-73's side effect is a mild tingling in the head or mild passing dizziness in some patients. I wouldn't mind a mild tingling while the misfolded proteins in my neural mitochondria regained proper form and function - I would be encouraged by it.

I do wish for every clinical trial to demonstrate genuine statistically meaningful therapeutic effect for the benefit of all patients.